SCHEMBL4405577

SCHEMBL4405577

CC(C)(C)NCC(O)COc1ccc2c(=O)cc(-c3ccc(O)c(O)c3)oc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.52
PARP1 P09874 2/20 0.52
ALOX5 P09917 2/20 0.52
TNKS2 Q9H2K2 2/20 0.52
POLH Q9Y253 2/20 0.52
CSNK2A2 P19784 1/20 0.49
CSNK2B P67870 1/20 0.49
CSNK2A1 P68400 1/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP3A4 P08684 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ST6GAL1 P15907 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
DHODH Q02127 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
FTO Q9C0B1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4406813 0.93 CSNK2A2 (0.50) TNKSPARP1ALOX5TNKS2POLH
SCHEMBL4399919 0.88 MEN1 (0.47) TNKSTNKS2KDM4EALDH1A1CYP3A4
SCHEMBL4415986 0.87 ADRB2 (0.61) TNKSPARP1ALOX5TNKS2POLH
SCHEMBL4412877 0.85 CYP3A4 (0.49) TNKSTNKS2KDM4EALDH1A1CYP3A4
SCHEMBL4405303 0.83 PABPC1 (0.56) CSNK2A2CSNK2BCSNK2A1
SCHEMBL11167135 0.83 MEN1 (0.54) MEN1KMT2AHTTCYP2D6
SCHEMBL4407561 0.82 CYP1A1 (0.48) MEN1KMT2ACYP2D6
SCHEMBL1483981 0.81 ADRB2 (0.52) MAPTMEN1KMT2ACYP2D6
SCHEMBL1483979 0.81 ADRB2 (0.52) MAPTMEN1KMT2ACYP2D6
SCHEMBL1483974 0.81 ADRB2 (0.52) MAPTMEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP claimed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP claimed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US claimed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO claimed
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 TNKS 4257/4885PARP1 4389/4885ALOX5 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.